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Introduction
Lung cancer is the leading cause of death from cancer in the United States and worldwide. Small-cell lung cancer (SCLC) accounts for 13.6% of all lung cancer cases (1, 2) . Compared to non-small-cell lung cancer (NSCLC), in which the 5-year survival rate is 18.0%, SCLC has only a 6.2% 5-year survival rate, and is characterized by a more rapid tumor growth rate and death from recurrent disease (3, 4) . Over the last several decades, there have been only modest improvements in patient survival (5) and no molecularly targeted therapy has proven beneficial for SCLC patients (3) . Nomogram prognostic models that predict patient outcomes may facilitate better treatment stratification and outcome evaluation, as well as more refined patient enrollment criteria for clinical trials in SCLC. Furthermore, a recent study in breast cancer (6) showed that user-friendly online prognostic tools could greatly enhance patient care.
However, currently there are no such online tools available for prognosis of SCLC.
To date there is only one study of nomograms in SCLC, published by Xie et al (4) , which developed two nomograms: one for extensive stage SCLC patients and the other for limited stage SCLC patients. The nomograms developed from that study provide useful tools for clinicians and researchers to stratify the risk of SCLC patients. However, the study simply classified patients as limited or extensive stage without using the more accurate TNM staging proposed by the International Association for the Study of Lung Cancer (IASLC) (7) . Furthermore, there is a lack of independent validation for this model, probably due to the limited sample size (n = 555 for extensive stage and n = 383 for limited stage).
Other non-nomogram prognostic models include the Manchester score and Spain score. However, both of these were developed on small sample sets (n = 407 for Manchester score and n = 341 for Spain score) and divide patients into only three risk groups (8, 9) .
The goal of this study was to identify prognostic factors for SCLC patients, and then develop and webserver. Compared to the previously published models, our model has the following advantages: 1) it was validated in an independent set; 2) it was developed and validated with a much larger sample size; 3) it was developed across multiple facilities and facility types, which greatly diminishes sample selection bias; 4) it utilizes accurate SCLC staging criteria: the AJCC 8 th edition TNM staging system proposed by IASLC (10); and 5) it provides an online webserver so that clinicians can use the nomogram model easily.
Methods

Source of data
202,194 SCLC cases were identified from NCDB and 34,380 of them met our inclusion criterion that they do not contain any missing data for selected variables. 
Model validation
To validate our model, three criteria were used to evaluate prediction performance in the testing set.
First, the cases were grouped according to their predicted risk score, and Kaplan-Meier survival curves
and Wald test were used to compare survival differences among the groups. Second, a concordance index (c-index) was calculated to estimate the similarity between the ranking of true survival time and of predicted risk score. Third, area under the curve (AUC) of time-dependent receiver operating characteristics (ROC) (16, 17) was calculated at each month from the 1 st to the 30 th month. Integrated AUC was calculated by averaging the 30 AUC values.
The other two models, the AJCC 8 th edition TNM staging system and the traditional limited/extensive staging system, were also tested for prognostic performance in the testing group. C-index and integrated AUC were used to compare this nomogram with the two staging systems. Here, extensive stage was defined based on the presence of distant metastases (M1 stage) (18, 19) . All other cases (M0 stage) were grouped as limited stage.
All computations were conducted in the R environment, version 3.3.2 (20) . R packages "survival"
(version 2.40-1) and "timeROC" (version 0.3) were used. Results with p-value ≤ 0.05 were considered statistically significant.
Implementation of this and previously published models
To facilitate researchers' and clinicians' usage of our model, we created a user-friendly webserver for our nomogram and the two models from Xie et al (4) . The nomogram from this study calculates the risk score, plots the survival curve and provides survival probabilities for 120 months at 6-month increments.
The Xie et al models for both extensive and limited stage cases provide 6-month and 12-month survival probabilities and predicted median survival time. Data points were read from Figures 1 and 2 of the Xie et al publication (4) , and the corresponding survival probability for a given score was calculated by linear interpolation.
Results
Characteristics of the training and validation cohorts
In total, 202,194 SCLC cases were identified in NCDB, among which, 34,380 cases that did not contain any missing variables were included in this study. Based on year of diagnosis, included cases were divided into two distinct groups: cases that were diagnosed from 2004 to 2011 (n = 24,680) were used as the training cohort, while cases that were diagnosed from 2012 to 2013 (n = 9,700) were used as the validation cohort. Characteristics of the two sets are shown in Table 1 . Demographic variables were similar between training and testing sets.
Building nomogram prognostic model in training cohort
In Table 3 ). The final risk score was calculated by adding up the score of each item using the nomogram depicted in Figure 1a .
The TNM stage defined by the AJCC 8 th edition contributed the most to the survival prognosis, followed by the treatment type and age. The predicted survival probability using the Cox regression model of risk scores was plotted in Figure 1b .
Validation in testing cohort
The proposed nomogram was validated in the independent testing set (n=9,700). The survival difference between any two adjacent groups, which were grouped by predicted risk score, was significant (p-value 
Discussion
In this study, a nomogram prognostic model was developed and validated using a large cohort of SCLC cases across the United States. This nomogram, based on routinely available demographic, staging and treatment information, predicts the survival probability for individual SCLC patients. The publicly accessible online implementation will assist clinicians in making treatment decisions.
Compared with other prognostic indexes, such as the Manchester Score (8) and the Spain prognostic index (9), our model calculates individualized survival probability rather than assigning cases into a few (Figure 1a) , with clear distinctions between each two adjacent TNM stages (Table 3) , and showed better prognostic performance than limited/extensive staging system with higher c-index and AUC (Figure 2b, Supplementary Table 2) . The significant contribution of TNM stage to this nomogram externally validates the performance of the 8 th edition TNM lung cancer classification system, and highlights the importance of applying this more accurate staging system to SCLC rather than using the traditional limited/extended staging (7, 10, 22) .
This proposed nomogram also illustrates the prognostic implications of using different treatment methods (Figure 1a, Table 3 ). As expected, cases treated with both surgery and chemo-radiation therapy have the lowest risk score and cases not treated with any method have the highest risk score. 
Conclusion
We developed a nomogram prognostic model for SCLC patients, and validated the model using an independent patient cohort. The proposed nomogram shows better prognostic performance than other existing models. This nomogram and previously published prognostic models were implemented on an online webserver. Researchers, clinicians and patients can easily predict the survival probability for each individual patient using this webserver. 
